Unlocking the Genetic Link: PON1 -108C/T Polymorphism and Cardiovascular Risk in Women Battling Polycystic Ovarian Syndrome

Abstract

An important enzyme linked to high-density lipoprotein (HDL) is called paraoxonase 1 (PON1); it is well-known for its
antioxidative qualities, which are vital in preventing oxidation of both HDL and low-density lipoprotein (LDL). In order to
investigate potential connections between PON1 genotyping and its activity and a number of medical disorders, such as diabetes,
cancer, heart disease, and fertility problems, more recent studies have focused on these topics. Genetic variations within the PON1
gene can disrupt metabolic processes, leading to imbalances between pro-oxidants and antioxidants, thereby potentially
contributing to increased cardiovascular risk. This study involves 56 control and 53 polycystic ovary syndrome (PCOS) affected
women, PON1 -108 C/T polymorphism frequencies were found using polymerase chain reaction (PCR) and restriction fragment
length polymorphism (RFLP) methods. Through evaluating enzyme activity and polymorphism, potential associations between
these two with cardiovascular risk. These findings revealed that both PCOS subjects and controls carrying the -108 TT genotype
demonstrated decreased paraoxonase activity compared to those harboring -108 C alleles. Additionally, the research demonstrated
a noteworthy correlation between the PON1 -108 C/T polymorphism and women with PCOS, suggesting its possible importance
as a cardiovascular risk factor in this particular population. These results underscore the critical importance of comprehending
genetic variations in PON1 and their implications for cardiovascular health, particularly in the context of PCOS. Further
investigation into the interplay between PON1 polymorphisms, enzyme activity, and cardiovascular risk may offer valuable
insights into preventive and therapeutic strategies tailored to address the unique needs of individuals, especially women, affected by PCOS.